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Chronic Subcutaneous B-Type Natriuretic Peptide
Horng H. Chen, MB, BCH,* James F. Glockner, MD,† John A. Schirger, MD,*
Alessandro Cataliotti, MD, PHD,* Margaret M. Redfield, MD,* John C. Burnett JR, MD*
Rochester, Minnesota
Objectives The purpose of the present study was to translate our laboratory investigations to establish safety and efficacy
of 8 weeks of chronic SC B-type natriuretic peptide (BNP) administration in human Stage C heart failure (HF).
Background B-Type natriuretic peptide is a cardiac hormone with vasodilating, natriuretic, renin-angiotensin inhibiting, and
lusitropic properties. We have previously demonstrated that chronic cardiac hormone replacement with subcuta-
neous (SC) administration of BNP in experimental HF resulted in improved cardiovascular function.
Methods We performed a randomized double-blind placebo-controlled proof of concept study comparing 8 weeks of SC
BNP (10 g/kg bid) (n  20) with placebo (n  20) in patients with ejection fraction 35% and New York Heart
Association functional class II to III HF. Primary outcomes were left ventricular (LV) volumes and LV mass deter-
mined by cardiac magnetic resonance imaging. Secondary outcomes include LV filling pressure by Doppler echo,
humoral function, and renal function.
Results Eight weeks of chronic SC BNP resulted in a greater reduction of LV systolic and diastolic volume index and
LV mass index as compared with placebo. There was a significantly greater improvement of Minnesota
Living with Heart Failure score, LV filling pressure as demonstrated by the reductions of E/e’ ratio, and
decrease in left atrial volume index as compared with placebo. Glomerular filtration rate was preserved
with SC BNP, as was the ability to activate plasma 3=,5=-cyclic guanosine monophosphate (p  0.05 vs.
placebo).
Conclusions In this pilot proof of concept study, chronic protein therapy with SC BNP improved LV remodeling, LV filling pres-
sure, and Minnesota Living with Heart Failure score in patients with stable systolic HF on optimal therapy. Renin-
angiotensin was suppressed, and glomerular filtration rate was preserved. Subcutaneous BNP represents a
novel, safe, and efficacious protein therapeutic strategy in human HF. Further studies are warranted to deter-
mine whether these physiologic observations can be translated into improved clinical outcomes and ultimately
delay the progression of HF. (Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strat-
egy; NCT00252187) (J Am Coll Cardiol 2012;60:2305–12) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.056The American Heart Association/American College of
Cardiology classification of heart failure (HF) Stage A to D
emphasizes the need to develop therapeutic strategies to
prevent the progression of HF (1). B-type natriuretic
peptide (BNP) is a 32-amino acid peptide produced mainly
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2012, accepted July 17, 2012.by cardiomyocytes and plays an important role in cardiore-
nal homeostasis. Specifically, BNP binds to the natriuretic
peptide-A receptor (NPR-A), which via 3=,5=-cyclic
guanosine monophosphate (cGMP) mediates natriuresis;
vasodilation; renin-angiotensin-aldosterone inhibition; and
anti-hypertrophic, anti-fibrotic, and positive lusitropic
properties (2). Despite activation of both plasma and cardiac
BNP in HF, exogenous administration of BNP resulted in
activation of its second messenger cGMP with favorable
cardiac unloading actions (3). In both experimental and
See page 2313
human HF, investigations have supported the hypothesis
that the synthetic capacity of the cardiomyocytes might be
overwhelmed in severe HF relative to the demands of the
system, leading to a state of relative deficiency of BNP (4).
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Subcutaneous BNP in Human Heart Failure December 4, 2012:2305–12Recent investigations have demon-
strated that, in severe HF, despite
high levels of immunoreactive BNP
detected in the plasma, there was
very little biologically active mature
BNP1-32—suggesting the presence
of abnormal molecular forms with
reduced biological actions (5–7).
Intravenous infusion of human
BNP (Nesiritide) is approved by the
U.S. Food and Drug Administra-
tion for the inpatient management
of acute decompensated congestive
heart failure (3). The FUSION I
and II studies (Follow-Up Serial In-
fusions of Nesiritide in Advanced
Heart Failure) evaluated the use of
outpatient serial intravenous infu-
sions of BNP in patients with Stage
D HF (8,9). Most recently, findings
of the 7,000-patient ASCEND
Trial (Acute Study of Clinical Ef-
fectiveness of Nesiritide in Decom-
pensated Heart Failure) reported
that 1- to 7-day infusion of BNP
was safe with no adverse renal or mortality properties and was
associated with modest improvement in dyspnea (10).
We have previously reported that subcutaneous (SC) ad-
ministration of BNP in experimental HF resulted in improved
cardiac output with reduced systemic vascular resistance and
cardiac filling pressures (11). Importantly, we translated these
studies to humans and completed a dosing finding study that
reported that acute SC administration of BNP at a dose of 10
g/kg in human Stage C HF resulted in increased plasma
BNP and cGMP and urinary cGMP excretion, associated with
favorable cardiorenal and humoral responses (12).
The objective of the present study was to further translate
our laboratory investigations to establish safety and efficacy of
8 weeks of chronic SC BNP administration in human Stage C
HF.
Methods
We performed a randomized double-blind placebo-controlled
proof of concept study comparing 8 weeks of SC BNP (10
g/kg) with SC placebo twice/day, in patients with ejection
fraction (EF) 35% and New York Heart Association
(NYHA) functional class II to III stable HF. Primary
outcomes were left ventricular (LV) volumes and LV mass
determined by cardiac magnetic resonance imaging (MRI).
Secondary outcomes include LV filling pressure by Doppler
echo, humoral function, and renal function. The protocol was
approved by the Mayo Clinic Institutional Review Board, and
informed consent was obtained from all participants.
Study protocol. From May 2003 to May 2008, recruitment
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
cGMP  3=,5=-cyclic
guanosine monophosphate
CRU  Clinic Research
Unit
GFR  glomerular filtration
rate
LA  left atrium/atrial
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
MLHF  Minnesota Living
with Heart Failure score
MRI  magnetic resonance
imaging
NYHA  New York Heart
Association
SC  subcutaneouswas limited to subjects 18 years of age and above with aresting left ventricular ejection fraction (LVEF) of 35% or
less and stable mild symptoms of HF (NYHA functional
class II and III). Subjects were admitted to the Clinic
Research Unit (CRU) at St. Mary’s Hospital, Mayo Clinic
CTSA, Rochester, Minnesota, the afternoon before the
scheduled active renal clearance study day. Cardiac MRI
was performed, and the 6-min walk and Minnesota Living
with Heart Failure (MLHF) Questionnaire was assessed.
On the following morning, the patients underwent a short
renal clearance test with Lothalamate Meglumine (Conray
60%) given subcutaneously to measure the glomerular fil-
tration rate (GFR). Echocardiography was performed for
determination of baseline LV filling pressure. Venous blood
samples were also collected for determination of BNP,
cGMP, and plasma renin activity. At the completion of the
short renal clearance test, the patients were randomized to
the SC BNP or placebo group. The patients were then
instructed about the proper technique for diluting the BNP
or placebo, and the SC injection was given in the anterior
abdominal wall. Thirty minutes after the first dose, a venous
blood sample for determination of BNP and cGMP was
drawn. The patients then self-administered the second dose
of SC BNP or placebo 12 h after the first dose. Subse-
quently, the third dose was self-administered under super-
vision 12 h later. The patients were then dismissed with
instructions and enough supplies for 8 weeks of SC admin-
istration twice/day.
Participants who experienced symptomatic hypotension
as defined by systolic BP 85 mm Hg or had symptoms of
lightheadedness or visual disturbances during the baseline
visit in the CRU were discontinued from the study.
At the end of the 8-week study period,3 days, the patients
were admitted to the CRU in the afternoon before the final
renal clearance study. In our previous pilot dose finding study
(12), we demonstrated that the blood pressure returned to
aseline 2 h after the administration of SC BNP. Hence, in
he current study, patients received their self-administered
C injection at least 2 h before the cardiac MRI, 6 min
alk, and MLHF Questionnaire assessment. The next
orning, echocardiography was performed, after which, a
hort renal clearance test and humeral determination were
arried out before and after a final dose of SC injection in
he same manner as the baseline study. The randomization
able was provided by the statistician, and it was created to
llow for a final n  20 in each group with completed
primary endpoint data.
Exclusion criteria specification. Exclusion criteria in-
clude: myocardial infarction (MI) within 3 months of
screening; unstable angina within 14 days of screening or
any evidence of myocardial ischemia; valvular stenosis,
hypertrophic, restrictive, or obstructive cardiomyopathy,
constrictive pericarditis, primary pulmonary hypertension,
or biopsy proven active myocarditis; sustained ventricular
tachycardia or ventricular fibrillation within 14 days of
screening; persistent atrial fibrillation; second- or third-
degree atrioventricular block without a permanent cardiac
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December 4, 2012:2305–12 Subcutaneous BNP in Human Heart Failurepacemaker; cardiovascular accident within 3 months of
screening or other evidence of significantly compromised
central nervous system perfusion; total bilirubin of 1.5
g/dl or an aspartate transaminase and alanine transami-
ase 1.5 the upper limit of normal; serum creatinine of
3.0 mg/dl; serum sodium of 125 mEq/dl or 160
Eq/dl; serum potassium of3.5 mEq/dl or5.0 mEq/dl;
erum digoxin level of 2.0 ng/ml; systolic pressure of 85
m Hg; LVEF 35% within 24 months of screening;
nable to self-administer SC injection twice/day; diagnosed
ith acquired immunodeficiency syndrome or known pos-
tive human immunodeficiency virus titer; other acute or
hronic medical conditions or laboratory abnormality that
ight increase the risks associated with study participation
r might interfere with interpretation of the data; received
n investigational drug within 1 month before dosing;
nable to undergo cardiac MRI; in the opinion of the
nvestigator, is unlikely to comply with the study protocol or
s unsuitable for any reasons.
nalytic methods. The concentration of iothalamate in
he plasma and urine collected during the short renal
learance test was determined with capillary electrophoresis
n the Mayo Renal laboratory for the determination of
FR. Specific plasma radioimmunoassays, including BNP,
GMP, and renin, were performed on the basis of previously
ublished methods by the co-investigator (12).
ssessment of LV filling pressure and left atrium volume
y echocardiography. Pulsed wave Doppler examination
f mitral (before and with Valsalva maneuver) and pulmo-
ary venous inflow as well as Doppler tissue imaging of the
itral annulus were performed. Left atrial (LA) volume was
alculated from 2-dimensional measurements and was in-
exed to body surface area as previously described (13).
ardiac MRI. Patients underwent cardiac MRI for mea-
urement of LVEF, LV end diastolic volume, LV end
ystolic volume, and LV mass. All examinations were
erformed with a 1.5-T MRI system (Signa Twin Speed
xcite, GE Healthcare, Waukesha, Wisconsin). After ini-
ial localization scans, short-axis cine images were obtained
t 8-mm intervals from base to apex with gated, balanced
teady state electrocardiography. Two-chamber, 3-chamber,
nd 4-chamber cine balanced steady-state free precession
cquisitions were then acquired with the short-axis images
or prescription. Images were transferred to a workstation
GE Advantage Windows, GE Healthcare), and a software
nalysis package (Mass Analysis, version 6, Medis, Leiden,
he Netherlands) was used to trace endocardial and epicar-
ial contours around each end-diastolic slice, and endocar-
ial contours around each end-systolic slice. The EF,
nd-systolic volume, end-diastolic volume, and LV mass
ere then computed by adding the contribution of the
ndividual slices. All cardiac MR images were reviewed in a
linded fashion (J.F.G.).
ata analysis. Continuous measurements that are normally
istributed are expressed as mean  SD, and those that are
kewed are expressed as median and quartiles, whereas cate- morical variables are reported as a number (percentage). Chi-
quare tests or Fisher exact tests were used to compare
ategorical variables between BNP group and placebo group,
hereas 2-sample t tests or rank sum tests were used to
ompare the continuous variables between the 2 groups.
omparisons from baseline to 8 weeks within groups were
ompleted with paired t tests for normally distributed variables
nd signed-rank tests for non-normal differences. A p value
0.05 was considered significant in this study.
esults
articipants. We randomized 45 patients to receive SC
NP (n  24) or SC placebo (n  21) injections twice/day
or 8 weeks. Three subjects in the BNP group developed
ymptomatic hypotension as defined by systolic BP 85
m Hg or had symptoms of lightheadedness or visual
isturbances during the baseline visit in the CRU and were
xcluded from the study as per protocol. One subject in the
NP group withdrew from the study for personal reasons.
ne subject in the placebo group had worsening HF
ymptoms during the 8-week period and withdrew from the
tudy. Hence, in the final analysis, we had n  20 in the
NP group and n  20 in the placebo group.
The baseline demographic and clinical characteristics
etween the study groups are similar, except for a higher
revalence of history of hypertension in the placebo group as
ompared with the BNP group (Table 1). However, despite
his difference, the baseline systolic and diastolic blood
ressure and heart rate were similar between the 2 groups.
he mean EF, plasma BNP levels, and distribution of
YHA functional class II versus class III patients were
imilar between the placebo and BNP groups. Most (95%)
atients were treated with an angiotensin-converting en-
yme inhibitor or angiotensin II receptor blocker or nitrates,
n combination with a beta-blocker and a diuretic. Approx-
mately 20% were also treated with spironolactone in each
roup. Eighty-five percent of the subjects in the BNP group
nd 80% of the subjects in the placebo group were receiving
arget doses of angiotensin-converting enzyme inhibitor/
ngiotensin II receptor blocker/nitrates, whereas 80% of the
ubjects in the BNP group and 85% of the subjects in the
lacebo group were receiving target doses of beta blockers.
ffects of SC BNP on LV structure and function. Figure 1
llustrates the change from baseline to 8 weeks of LV
tructure and function as assessed by MRI. Eight weeks of
hronic SC BNP administered twice daily resulted in a
ignificantly greater reduction in LV end-systolic volume
ndex as compared with placebo (BNP group: 5  13
l/m2 vs. placebo group: 6  10 ml/m2, p  0.004).
Similarly, there was a greater reduction in LV end-diastolic
volume (10  15 ml/m2) in the BNP group as compared
ith the placebo group (6  12 ml/m2) at 8 weeks
compared with baseline (p  0.001). These reductions in
V volumes were associated with a greater decrease in LV
ass index in the BNP group (4  10 mg/m2) as
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Subcutaneous BNP in Human Heart Failure December 4, 2012:2305–12compared with the placebo group (6  13 mg/m2) (p 
0.006). The LVEF was unchanged in both the BNP and
placebo groups. The aforementioned changes in LV struc-
ture occurred in the absence of significant changes from
baseline to 8 weeks; in heart rate (BNP group: 67  12
beats/min to 65  12 beats/min; placebo group: 74  12
beats/min to 73  14 beats/min); systolic blood pressure
BNP group: 140  20 mm Hg to 135  25 mm Hg;
lacebo group: 121 17 mm Hg to 126 15 mm Hg) and
iastolic blood pressure (BNP group: 79  12 mm Hg to
7  13 mm Hg; placebo group: 74  12 mm Hg to 75 
2 mm Hg) measured when the MRI was performed.
Figure 2 illustrates echocardiographic assessment of LV
lling pressure. The SC BNP improved LV filling pressure
s demonstrated by a greater reduction of Doppler mitral
nflow velocity (E) to mitral annulus tissue Doppler velocity
e’) ratio E/e’ and the greater decrease in LA volume index
ompared with placebo. The aforementioned changes oc-
urred in the absence of significant changes from baseline to
weeks; in heart rate (BNP group: 62 15 beats/min to 66
eats/min  13 beats/min; placebo group: 66  11 beats/
in to 70  11 beats/min); systolic blood pressure (BNP
roup: 133  20 mm Hg to 129  36 mm Hg; placebo
Baseline CharacteristicsTable 1 Baseline Characteristics
Baseline Characteristics
Placebo
(n  20)
BNP
(n  20) p Value
Female 8 (40) 4 (20) 0.17
NYHA functional class II 10 (50) 12 (60) 0.53
NYHA functional class III 10 (50) 8 (40) 0.55
LVEF (%) 31 7 32 9 0.79
Systolic blood pressure (mm Hg) 125 16 133 17 0.14
Diastolic blood pressure (mm Hg) 70 11 73 11 0.34
Heart rate (beats/min) 69 12 66 13 0.59
Plasma BNP (pg/ml) 57 (20,250) 51 (15,121) 0.67
GFR (ml/1.73 m2) 78 21 74 23 0.59
History of PVD 1 (5) 2 (10) 0.55
History of COPD 1 (5) 2 (10) 0.55
Ischemic cardiomyopathy 10 (50) 10 (50) 1.00
History of hypertension 16 (80) 8 (40) 0.010
History of arrhythmia 4 (20) 5 (25) 0.70
History of smoking 7 (35) 9 (45) 0.52
History of diabetes 7 (35) 9 (45) 0.52
History of high cholesterol 16 (80) 13 (65) 0.29
ACEI or Angio II or nitrates 19 (95) 20 (100) 0.31
Digoxin 8 (42) 7 (35) 0.65
Beta blocker 19 (95) 20 (100) 0.31
Diuretic (loop) 14 (70) 15 (75) 0.72
Coumadin 1 (6) 2 (13) 0.48
Spironolactone 4 (20) 4 (21) 0.94
Diuretic (thiazide) 3 (16) 4 (20) 0.73
Antiarrhythmics 0 (0) 5 (25) 0.017
Values are n (%), mean  SD, or median (quartiles).
ACEI  angiotensin converting enzyme inhibitor; Angio II  angiotensin II receptor blocker;
BNP  B-type natriuretic peptide; COPD  chronic obstructive pulmonary disease; GFR 
glomerular filtration rate; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association; PVD  peripheral vascular diseases.roup: 123 16 mm Hg to 123 15 mm Hg) and diastoliclood pressure (BNP group: 72  13 mm Hg to 74  12
m Hg; placebo group: 69 11 mm Hg to 69 12 mm Hg)
easured at the time when the echo was performed.
ffects of SC BNP on clinical well-being. The MLHF
core was assessed at baseline and at 8 weeks. Chronic SC
NP administration resulted in a greater improvement of
LHF as compared with the placebo group at 8 weeks.
pecifically, there was a greater decrease of the MLHF score in
he BNP group (9  12) as compared with the placebo
roup (1  14) (BNP vs. placebo p  0.013). There was a
rend for a greater increase in 6-min walk distance in the BNP
roup versus placebo (2.2 70 m vs. 0.49 37 m, p 0.091).
ffects of SC BNP on neurohumoral parameters. The
C BNP administration resulted in the increase of the
econd messenger, plasma cGMP levels both at time of first
osing and with the last dosing at 8 weeks (Fig. 3). Thus, 8
eeks of twice daily administration of SC BNP did not
esult in the development of tolerance to BNP as demon-
trated by a similar activation of the second messenger
GMP, after 8 weeks as compared with baseline. There was
greater decrease in plasma renin activity with SC BNP
ompared with placebo at 8 weeks (4  7 ng/ml/h vs.
2  5 ng/ml/h, p  0.005).
ffects of SC BNP on renal function. Glomerular filtra-
ion rate (GFR) as determined by iothalmate clearance was
reserved with SC BNP (6.9  14 ml/1.73 m2) with a
rend toward a greater increase at 8 weeks as compared with
lacebo (2.8  25 ml/1.73 m2) (p  0.14 BNP vs.
placebo). In addition, plasma cystatin C trended to decrease
in the BNP group (0.04  0.2 mg/dl, n  16) at 8 weeks,
whereas it trended to increase in the placebo group
(0.09  0.2 mg/dl, n  18) (p  0.1 BNP vs. placebo).
Serious adverse events and adverse events. SERIOUS
DVERSE EVENTS. Three subjects in the BNP group devel-
oped hypotension as defined by systolic BP 85 mm Hg or
had symptoms of lightheadedness or visual disturbances
during the baseline visit in the CRU and were excluded
from the study as per protocol. All subjects recovered with
placement at Trendelenburg position and fluid administra-
tion without any clinical consequences. One subject in the
placebo group had worsening HF symptoms during the
8-week period and withdrew from the study.
ADVERSE EVENTS. Adverse events are reported in Table 2.
There was a strong trend for higher incidences of lighthead-
edness in the BNP group as compared with the placebo
group. However, it must be noted that, in these patients, it
did not result in the discontinuation of the study drug. In
the placebo group, more patients developed fatigue and
shortness of breath as compared with the BNP group.
However, this did not achieve statistical significance.
Discussion
In this proof of concept human study, 8 weeks of protein
therapy with SC BNP administered twice daily improved
LV remodeling, diastolic function, and clinical symptoms
2309JACC Vol. 60, No. 22, 2012 Chen et al.
December 4, 2012:2305–12 Subcutaneous BNP in Human Heart Failure(i.e., MLHF score) in patients with stage C systolic HF on
optimal medical therapy. Furthermore, plasma renin activity
was suppressed, and GFR was preserved. Importantly, there
was no development of tolerance to chronic SC BNP
Figure 1 Effects of SC BNP on LV Structure and Function
Changes in left ventricular (LV) end-systolic volume index (*p  0.004), LV end-dia
fraction from baseline to 8 weeks in B-type natriuretic peptide (BNP) and placebo
Figure 2 Change in LV Doppler E/e’ Ratio and LA Volume Inde
Change in left ventricular (LV) Doppler E/e’ ratio (*p  0.001) and left atrium (LA)
(BNP) and placebo groups. The dot within each box represents the mean value, w
outside the box. *p value BNP versus placebo.administration as evident by a preserved activation of
cGMP, its second messenger after 8 weeks of therapy.
Despite recent advances in the treatment of overt symp-
tomatic (Stage C/D) HF, mortality and morbidity among
volume index (*p  0.001), LV mass index (*p  0.006), and LV ejection
. *p value BNP versus placebo. SC  subcutaneous.
e index (*p  0.003) from baseline to 8 weeks in B-type natriuretic peptide
s the horizontal line within each box represents the median value and quartilesstolic
groupsx
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Subcutaneous BNP in Human Heart Failure December 4, 2012:2305–12patients with HF remains high. Our study addresses the
concept of reverse LV remodeling with chronic administra-
tion of the cardiac peptide BNP as novel protein therapy for
stage C systolic HF. The rationale for using BNP as a novel
protein therapeutic for reducing LV remodeling was also
strengthened by our pilot study, which reported that a 3-day
infusion of BNP in humans with first-time anterior acute
MI was associated with reduced LV systolic and diastolic
volumes 1 month after acute MI (14).
The current study is the first to report the potential
favorable LV remodeling actions of chronic BNP adminis-
tration in human stage C systolic HF. The degree of LV
remodeling seen in the current study is comparable to a
previous MRI sub-study of the MERIT-HF (Metoprolol
CR/XL Randomized Intervention Trial in Heart Failure).
In that sub-study (n  41), Groenning et al. (15) reported
a reduction in LV end-systolic volume index of9.7 ml/m2
and LV end-diastolic volume index of 10 ml/m2 at 5 to 7
weeks after therapy. In the current study, we report a
reduction in left LV end-systolic volume index of 5  13
ml/m2 and a reduction in LV end-diastolic volume (10 
5 ml/m2) in the BNP group after 8 weeks of therapy. In a
recent meta-analysis by Kramer et al. (16), they reported
that a decrease of 10 ml in the mean change of end-diastolic
volume was associated with a 1.9-fold (95% confidence
interval: 1.2 to 3.2, p  0.012) increased odds that an
ntervention would have significantly favorable effects on
ortality. Furthermore, a decrease of 10 ml in the mean
nd-systolic volume change corresponded to a relative odds
atio of 0.96 for mortality (95% confidence interval: 0.93 to
Figure 3 Plasma cGMP in the BNP Group
at Baseline and 8 Weeks
Plasma 3=,5=-cyclic guanosine monophosphate (cGMP) in the B-type natri-
uretic peptide (BNP) group at baseline (*p  0.001) and 8 weeks (*p 
0.001), pre-injection and 30 min post-injection. The dot within each box
represents the mean value, whereas the horizontal line within each box
represents the median value and quartiles outside the box. *p value pre-
injection versus post-injection..98, p  0.01). Plasma renin activity was suppressed to areater extent in the BNP group as compared with the
lacebo group. The effects of BNP on LV structure might
e due to the indirect unloading and diuretic effects of BNP.
n the current study, we did not have to reduce the dose of
iuretics in any patients. However; we did not have to
ncrease the dose of the diuretics as well. The diuretic and
atriuretic actions of BNP might have resulted in decreased
lling pressure in the LV contributing to the improved
emodeling. Unfortunately, we did not measure the plasma
olume of the patients. These findings confirm and extend
revious preclinical studies that reported that BNP acting
ia the NPR-A has potent anti-hypertrophic and anti-
brotic properties. Specifically, NPR-A is present on car-
iomyocytes (17,18), and incubation with BNP suppresses
he response to hypertrophic factors in isolated cardiomyoc-
yes (19). Furthermore, we and others have demonstrated
hat cardiomyocyte specific disruption of NPR-A results in
xaggerated hypertrophy and fibrosis in response to cardiac
tress (20). These studies suggest that the cardiac hormone
NP regulates myocardial structure by direct anti-
ypertrophic effects on the cardiomyocyte, which comple-
ent their effects to reduce load and suppress pro-
ypertrophic humoral factors. Furthermore, transcripts for
PR-A are also present in isolated fibroblasts (18), and in
itro studies have demonstrated that BNP provides broad
pposition to fibroblast activation and collagen production
21). Thus, direct actions of BNP on both the cardiomyo-
yte and the fibroblast might contribute to the anti-
ypertrophic and anti-fibrotic effects of BNP. However,
ithout a washout time for the SC BNP, we cannot exclude
hat the acute unloading effects of BNP might account for
he changes in LV systolic and diastolic volumes. However,
ssessment of LV mass index by MRI is not affected by
cute loading conditions. Hence, the greater decrease in LV
ass index in the BNP group as compared with the placebo
roup might suggest that SC BNP has a favorable effect in
he LV mass. There was no significant correlation between
aseline systolic blood pressure and the changes in LV
ystolic and diastolic volumes and mass index at 8 weeks.
In the current study, 8 weeks of chronic BNP adminis-
ration also resulted in an improvement of LV filling
Adverse EventsTable 2 Adverse Events
BNP (n  20) Placebo (n  20) p Value
Lightheadedness 3 (15%) 0 (0%) 0.07
SOB and fatigue 3 (15%) 7 (35%) 0.14
Injection site sting/itchy 4 (20%) 3 (15%) 0.68
Flu-like symptoms 1 (5%) 2 (10%) 0.55
Flushing 3 (15%) 1 (5%) 0.29
Loose stools 2 (10%) 0 (0%) 0.15
Atrial fibrillation 0 (0%) 1 (5%) 0.31
Hyperkalemia 1 (5%) 1 (5%) 1.00
Edema 1 (5%) 0 (0%) 0.31
Other symptoms 2 (10%) 2 (10%) 1.00SOB  shortness of breath.
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ratios and LA volume index in the BNP group as compared
with the placebo group. Studies in isolated cardiomyocytes
preparations report improvement in the speed of myocyte/
myocardial relaxation (22) and increases in resting cell
length after BNP or cGMP exposure. In in vivo studies in
experimental canine HF, we have described the pro-
lusitropic effects of BNP (23). Additionally, a key integrated
physiological study demonstrated that, in patients with
isolated diastolic dysfunction, infusion of BNP significantly
attenuated the increase in pulmonary capillary wedge pres-
sure during exercise, without an effect on resting hemody-
namic status (24). These findings suggest possible direct and
indirect effects to improve operant diastolic function.
Hence, the greater improvement of LV structure and filling
pressure in the BNP group might account for the improve-
ment in MLHF scores as compared with the placebo group.
The findings of the current study are different from the
ASCEND and FUSION studies (9,10). However, there are
major differences in the patient population, route, dose, and
duration of administration of BNP in the 3 studies. The
current study recruited stable NYHA functional class II to
III patients, whereas the patients in both the FUSION and
ASCEND studies were NYHA functional class III to IV.
In the FUSION study, the patients received once/week
infusions, whereas in the ASCEND study, they received up
to 6 days of infusion. In our current pilot study, the patients
received twice/day SC administration for 8 weeks.
There was no development of tolerance to 8 weeks of
twice daily SC BNP administration as evident by a pre-
served activation of cGMP, its second messenger. This is
consistent with our previous findings in a canine model of
HF where we demonstrated that 10 days of SC BNP
administration did not result in the development of toler-
ance (25). In the current study, we demonstrated that 8
weeks of SC BNP preserved GFR with a strong trend for
GFR to improve and plasma cystatin C to decrease as
compared with placebo.
Three (12.5%) of the subjects did not tolerate 10 /kg
bolus SC BNP injections and were excluded from the study
as per study protocol. Another 3 (12.5%) subjects developed
symptoms of lightheadedness during the 8 week period,
which resolved without withdrawal of study drug. One
subject in the placebo group withdrew from the study due to
worsening HF symptoms, and there was a trend for more
subjects in the placebo group developing symptoms of
worsening shortness of breath or fatigue as compared with
the BNP group. Indeed, in the ASCEND trial, there was
significantly greater symptomatic and asymptomatic hypo-
tension in the BNP-treated group compared with placebo.
Therefore, a limiting factor of the use of BNP in our study
and others is hypotension. Further studies are required to
test lower doses of SC BNP.
Study limitations. This study was designed as a transla-
tional proof of concept investigation of the chronic use of
twice daily SC BNP administration in patients with stage Csystolic HF and not as a definitive clinical trial, because the
sample size is small. Furthermore, we only tested a single
dose at 10 /kg. Further studies that are adequately pow-
ered to evaluate potential clinical efficacy in HF are war-
ranted. Due to limited resources and funding, we were not
able to include an active drug run-in period before random-
ization of the subjects to the treatment groups, and hence
we were not able to do an intention to treat analysis, which
is a limitation of the study design. Because of the use of
MRI, none of our patients had a defibrillator or biventricu-
lar pacing. With the results from the recently published
EMPHASIS (Eplerenone in Mild Patients Hospitalization
and Survival Study in Heart Failure) trial (26), our patient
population should be treated with spironolactone antago-
nist; however, only 20% of them were taking a spironolac-
tone antagonist.
Conclusions
This proof of concept pilot study is the first to demonstrate
that SC BNP administration represents a novel, safe, and
efficacious protein therapeutic strategy in human stage C
systolic HF with favorable actions of myocardial structure
and function and patient well-being. Further studies are
warranted to determine whether these functional responses
can be translated into improved clinical outcomes contrib-
uting to delaying the progression of HF.
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